NASDAQ$MDXG
Mimedx Group Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Mimedx reported a stellar first quarter with robust net sales growth and disciplined expense management.
MiMedx Group, Inc. announced strong first quarter 2024 results, with net sales of $85 million, representing an 18% increase year-over-year. The company reported GAAP net income of $9 million and an Adjusted EBITDA of $19 million, or 22% of net sales. They also expanded their portfolio with a distribution agreement for a new xenograft product.
- Net sales for Q1 2024 reached $85 million, an 18% increase year-over-year.
- GAAP net income for Q1 2024 was $9 million, resulting in a net margin of 11%.
- Adjusted EBITDA for Q1 2024 was $19 million, representing 22% of net sales.
- The company expanded its portfolio through a distribution agreement with Regenity Biosciences for a collagen particulate xenograft product.
Headline financials
Revenue & EPS history
Mimedx · Revenue · Quarterly
$84.7M
Forward guidance
MIMEDX is positioned well for another successful year and long-term growth due to the clinical strength of its product portfolio, the effectiveness of its commercial organization, a solid financial foundation, and the pending launch of its xenograft product into the Surgical market.
Tailwinds
- Clinical strength of product portfolio
- Effectiveness of commercial organization
- Solid financial foundation
- Pending launch of xenograft product into the Surgical market
- Disciplined expense management
Headwinds
- Future sales are uncertain and affected by competition
- Access to customers and healthcare providers can vary
- Reimbursement environment fluctuations
- Scientific research results are uncertain and may have little or no value
- Ability to sell products in other countries depends on reimbursement levels and market acceptance
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+1.7%
Avg return
Earnings day
+2.9%
Avg return
5 days after
+7.2%
Avg return
30 days after
53%
34 / 64 earnings
Positive
+37.9%
Q1 2023
Best reaction
-23.3%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.1% | +6.2% | +8.2% | |
| Q4 2025 | -0.9% | -8.8% | -28.8% | |
| Q3 2025 | +2.6% | +7.0% | -4.3% | |
| Q1 2025 | -8.1% | -3.9% | -6.5% | |
| Q4 2024 | +1.6% | +1.1% | -5.9% | |
| Q3 2024 | +17.9% | +22.7% | +59.2% | |
| Q2 2024 | -12.0% | -17.7% | -9.9% | |
| Q1 2024 | +16.8% | +17.7% | +13.7% | |
| Q4 2023 | -2.9% | -1.7% | -8.3% | |
| Q3 2023 | +6.7% | +10.9% | +26.5% | |
| Q2 2023 | -4.6% | -4.2% | -8.1% | |
| Q1 2023 | +37.9% | +49.1% | +50.4% | |
| Q4 2022 | -11.4% | -6.4% | -29.0% | |
| Q3 2022 | -3.6% | +1.3% | +12.6% | |
| Q2 2022 | +8.2% | +15.5% | +2.3% | |
| Q1 2022 | +11.1% | -8.9% | -4.8% | |
| Q4 2021 | +1.4% | -1.6% | -4.0% | |
| Q3 2021 | +18.8% | +22.6% | +2.5% | |
| Q2 2021 | -2.5% | +1.4% | +23.4% | |
| Q1 2021 | -2.9% | -5.0% | +2.0% | |
| Q4 2020 | -15.3% | -13.4% | +13.8% | |
| Q3 2020 | +3.4% | -8.2% | -5.6% | |
| Q2 2020 | +2.3% | +4.2% | +14.4% | |
| Q2 2018 | +8.2% | +3.2% | +18.2% | |
| Q1 2020 | +8.2% | +3.2% | +18.2% | |
| Q4 2018 | +8.2% | +3.2% | +18.2% | |
| Q4 2019 | +8.2% | +3.2% | +18.2% | |
| Q2 2019 | +8.2% | +3.2% | +18.2% | |
| Q1 2018 | +8.2% | +3.2% | +18.2% | |
| Q1 2019 | +8.2% | +3.2% | +18.2% | |
| Q3 2019 | +8.2% | +3.2% | +18.2% | |
| Q4 2017 | -21.6% | -22.1% | -14.0% | |
| Q3 2018 | -1.3% | -8.6% | -7.0% | |
| Q3 2017 | +4.1% | +8.7% | -4.9% | |
| Q2 2017 | +0.7% | +2.1% | +5.9% | |
| Q1 2017 | +8.2% | +19.1% | +17.5% | |
| Q4 2016 | -3.9% | +3.4% | +9.8% | |
| Q3 2016 | +4.9% | +8.0% | +19.1% | |
| Q2 2016 | -0.9% | -1.7% | -5.6% | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | -0.4% | — | — | |
| Q3 2015 | -23.3% | — | — | |
| Q2 2015 | -13.5% | — | — | |
| Q1 2015 | +0.9% | — | — | |
| Q4 2014 | +8.7% | — | — | |
| Q3 2014 | +13.2% | — | — | |
| Q2 2014 | +5.5% | — | — | |
| Q1 2014 | -3.8% | — | — | |
| Q4 2013 | +2.2% | — | — | |
| Q3 2013 | -3.5% | — | — | |
| Q2 2013 | +0.8% | — | — | |
| Q1 2013 | -2.2% | — | — | |
| Q4 2012 | +8.5% | — | — | |
| Q3 2012 | +13.5% | — | — | |
| Q2 2012 | -4.8% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | -4.2% | — | — | |
| Q2 2011 | -2.5% | — | — | |
| Q1 2011 | -3.7% | — | — | |
| Q4 2010 | +5.8% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | -4.8% | — | — | |
| Q1 2010 | +4.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro